Patents matching “anti-”

US 11851498

Anti-CD276 antibodies (B7H3)

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Dec 26, 2023 · Expires Dec 21, 2043

US 11839660

Anti-transferrin receptor antibody and uses thereof

Dyne Therapeutics, Inc. · Granted Dec 12, 2023 · Expires Dec 7, 2043

US 11840561

Anti-KRAS-G12D T cell receptors

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Dec 12, 2023 · Expires Dec 7, 2043

US 11839642

Anti-angiogenin peptides, compositions, and methods of use

The Board of Regents of the University of Oklahoma · Granted Dec 12, 2023 · Expires Dec 7, 2043

US 11834507

Anti-MET agonist antibody for use in the treatment of colorectal cancer

AGOMAB THERAPEUTICS · Granted Dec 5, 2023 · Expires Nov 30, 2043

US 11834512

Inhibiting anti-ENPP1 antibodies

The Regents of the University of California · Granted Dec 5, 2023 · Expires Nov 30, 2043

US 11827683

Bi-functional anti-tau polypeptides and use thereof

REGENERATIVE RESEARCH FOUNDATION · Granted Nov 28, 2023 · Expires Nov 23, 2043

US 11820826

Anti-NPR1 antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Nov 21, 2023 · Expires Nov 16, 2043

US 11813235

Guanfacine as an anti-virulence agent

THE TRUSTEES OF PRINCETON UNIVERSITY · Granted Nov 14, 2023 · Expires Nov 9, 2043

US 11814432

Anti-HLA-A2 antibodies, related chimeric antigen receptors, and uses thereof

SANGAMO THERAPEUTICS FRANCE · Granted Nov 14, 2023 · Expires Nov 9, 2043

US 11814428

Anti-PTCRA antibody-drug conjugates and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Nov 14, 2023 · Expires Nov 9, 2043

US 11814439

Anti-CD20 antibody compositions

TG Therapeutics, Inc. · Granted Nov 14, 2023 · Expires Nov 9, 2043

US 11807689

Anti-CD20 antibody compositions

TG Therapeutics, Inc. · Granted Nov 7, 2023 · Expires Nov 2, 2043

US 11802158

Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and methods of using the same

CytomX Therapeutics, Inc. · Granted Oct 31, 2023 · Expires Oct 26, 2043

US 11795215

Anti-mesothelin chimeric antigen receptor specifically binding to mesothelin

CELLENGENE INC. · Granted Oct 24, 2023 · Expires Oct 19, 2043

US 11795233

Muscle-targeting complex comprising an anti-transferrin receptor antibody linked to an oligonucleotide

Dyne Therapeutics, Inc. · Granted Oct 24, 2023 · Expires Oct 19, 2043

US 11795234

Methods of producing muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide

Dyne Therapeutics, Inc. · Granted Oct 24, 2023 · Expires Oct 19, 2043

US 11787867

Anti-GITR antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Oct 17, 2023 · Expires Oct 12, 2043

US 11773185

Anti-BACE1 antibodies and methods of use thereof

DENALI THERAPEUTICS INC. · Granted Oct 3, 2023 · Expires Sep 28, 2043

US 11771762

Anti-ErbB3 antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Oct 3, 2023 · Expires Sep 28, 2043

US 11773156

Anti-hemagglutinin antibodies and methods of use thereof

REGENERON PHARMACEUTICALS, INC. · Granted Oct 3, 2023 · Expires Sep 28, 2043

US 11766558

Biomedical electrode with anti-microbial properties

COMPASS HEALTH BRANDS CORP. · Granted Sep 26, 2023 · Expires Sep 21, 2043

US 11769597

Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF

REGENERON PHARMACEUTICALS, INC. · Granted Sep 26, 2023 · Expires Sep 21, 2043

US 11753474

Anti-Dectin-2 antibodies

Bolt Biotherapeutics, Inc. · Granted Sep 12, 2023 · Expires Sep 7, 2043